Unique ID issued by UMIN | UMIN000008477 |
---|---|
Receipt number | R000009452 |
Scientific Title | Clinical study of selegiline hydrochloride ( FP OD tablet 2.5) to flexion of spine in Parkinson's disease. |
Date of disclosure of the study information | 2012/07/19 |
Last modified on | 2015/09/22 09:15:26 |
Clinical study of selegiline hydrochloride ( FP OD tablet 2.5) to flexion of spine in Parkinson's disease.
Clinical study of selegiline to flexion of spine in Parkinson's disease.
Clinical study of selegiline hydrochloride ( FP OD tablet 2.5) to flexion of spine in Parkinson's disease.
Clinical study of selegiline to flexion of spine in Parkinson's disease.
Japan |
Parkinson disease
Neurology |
Others
NO
To evaluate effectiveness of selegiline hydrochloride (FP OD tablet 2.5) to the flexion of spine associated with Parkinson's disease. We use stabilometory to evaluate it objectively
Efficacy
Confirmatory
Rsults of stabilometry (Gravicoder GS-3000; AeNIMA)
1. Modified Hoehn & Yahr stage of Parkinson's Disease
2. Iapanese version, UPDRS Part I, Part II, Part III, Part IV
3. Degree of posture flexion (degree of antero flexion/ degree of side flexion) using photo.
4. Pain evaluation with VAS scale.
5. Safety evaluation, side effects.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Selegiline hydrochloride 5mg 8weeks, 7.5mg 8weeks and stop it, followed after 8weeks, and evaluate each points.
20 | years-old | <= |
Not applicable |
Male and Female
1) Patients diagnosed as Parkinson' s disease and classified into Modified Hohen & Yahr staging Scale I through
2) Patients whose symptom of posture disorder is latent in supine position
3) Patients aged 20 or over when their consents given
4) Hospitalized patients/outpatients
1) Patients receiving drugs prohibited for concomitant
2) Patients who have lumber spine deformation evaluated by an X-ray examination
3) Patients whit orthostatic
hypotension
4) Patients receiving medical
treatment for epilepsy
5) Patient who have symptoms of
serious nerve and / or psychiatric
disorders such as disturbance of
consciousness , hallucination ,
delusions and abnormal behavior
6) Patient with severs disease of
heart , blood vessels , liver , renal ,
blood and other life-threatening
diseases
7) Patients who have or had
schizophrenia
8) Patients who have or had addiction to central nerve system stimulants such as cocaine
9) Patients who are pregnant during the period of study
10) Patients addiction to alcohol or drugs
11) Patients who are determined as unfit for the study by attending physicians for reasons other than those stated above
20
1st name | |
Middle name | |
Last name | Asako Yoritaka |
Juntendo Koshigaya Hospital
Neurology
Fukuroyama 560, Koshigaya-shi, Saitama, Japan
+81-48-975-0321
ayori@juntendo.ac.jp
1st name | |
Middle name | |
Last name | Asako Yoritaka |
Juntendo Koshigaya Hospital
Neurology
Fukuroyama 560, Koshigaya-shi, Saitama, Japan
+81-48-975-0321
ayori@juntendo.ac.jp
Department of Neurology, Juntendo Koshigaya Hospital
Department of Neurology, Juntendo Koshigaya Hospital
Self funding
NO
順天堂大学附属順天堂越谷病院 神経内科外来
2012 | Year | 07 | Month | 19 | Day |
Unpublished
Completed
2012 | Year | 05 | Month | 29 | Day |
2012 | Year | 07 | Month | 19 | Day |
2014 | Year | 12 | Month | 19 | Day |
2015 | Year | 09 | Month | 10 | Day |
2012 | Year | 07 | Month | 19 | Day |
2015 | Year | 09 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009452
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |